Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00674635

Recruitment Status : Completed

First Posted : May 8, 2008

Last Update Posted : December 1, 2016

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

Study Description

Brief Summary:

This is a randomized, double-blinded, placebo-controlled adaptive, dose finding study to investigate the safety, tolerability, PK, PD and efficacy of single and repeat intravenous infusions of GSK315243A in patients with active rheumatoid arthritis. The study is divided into 2 parts: Part A is an adaptive, dose finding phase which will provide safety, tolerability, PK and PD on single intravenous infusions. Part B is a repeat dose phase which will provide safety, tolerability, PK, PD and efficacy following repeat intravenous infusions of a selected dose level.

Condition or disease	Intervention/treatment	Phase
Arthritis, Rheumatoid	Drug: GSK3152314A Drug: Placebo	Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	135 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)
Study Start Date :	April 2008
Actual Primary Completion Date :	December 2010
Actual Study Completion Date :	December 2010

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Rheumatoid arthritis

MedlinePlus related topics: Arthritis Rheumatoid Arthritis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo matching placebo	Drug: Placebo matching placebo
Active Comparator: GSK315234A Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose	Drug: GSK3152314A Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose

Outcome Measures

Primary Outcome Measures :

• To assess the safety and tolerability of GSK315234A after single and repeat intravenous infusions in subjects with active rheumatoid arthritis on a background of methotrexate. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
safety assessment includes AEs, vital signs, ECG, clinical laboratory tests.
• To assess the effect of GSK315234A on disease activity [as defined by Disease Activity Score (DAS) 28 score] on Day 28 after a single intravenous infusion [ Time Frame: Part A total of 150 days ]
DAS28 at Day 28 and DAS28 at Day 56
• To assess the effect of GSK315234A on disease activity [as defined by Disease Activity Score (DAS) 28 score] on Day 56 in subjects with active rheumatoid arthritis on a background of methotrexate (Part B and Part C). [ Time Frame: Part B total of 236 days and Part C total of 180 days ]
DAS28 scores on Day 56 (Part B and C)

Secondary Outcome Measures :

Weighted mean DAS28 after single and repeat intravenous doses [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Plasma PK parameters of GSK315234A after single and repeat intravenous doses including free, and bound GSK315234A (serum) concentrations, AUC(0-¥), Cmax, clearance, volume of distribution and accumulation ratio [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
DAS28 and EULAR response criteria after single and repeat intravenous doses [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
ACR20/ACR50/ACR70 response after single and repeat intravenous doses [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Number of swollen joints assessed using 28-joint counts. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Number of tender/painful joints assessed using 28-joint counts. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Subject's pain assessment [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Physician's global assessment of arthritis condition. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Patients' global assessment of arthritis condition. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Functional disability index (Health Assessment Questionnaire) [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
C-reactive Protein (CRP). [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
ESR [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Global Fatigue Index [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
HAQ disability index [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Pharmacodynamic biomarkers after single and repeat intravenous doses: [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Characteristic AUC50 and EC50 for clinical endpoint changes with plasma exposure model, as assessed by sigmoid Emax and indirect response PK/PD models. [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
Immunogenicity (Human anti-GSK315234A antibodies) [ Time Frame: Part A total of 150Days; Part B total of 236 days and Part C total of 180 days ]
• To assess the relative bioavailability of GSK315234A administered subcutaneously (Part C) as compared to intravenous administration in subjects with active rheumatoid arthritis on a background of methotrexate [ Time Frame: Part C total of 180days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females between 18 and 75 years of age, inclusive.
All subjects must use acceptable contraception (as defined in the study restriction section) to ensure that no pregnancies occur during the course of the study and for at least 12 weeks after dosing for males and for 32 weeks after dosing for females (see Section 7.1 on contraception for more details).
Body mass index within the range 18.5 - 35 kg/m2 inclusive, in addition to a weight range of 55 - 95kg.
The subject must be capable of giving informed consent and can comply with the study requirements and timetable.
The subject must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology (ACR) (see Appendix 2).
The subject must have a DAS28 disease activity score of greater than 4.2 at screening and pre-dose.
The subject must have a CRP serum level of >/0.5mg/dl or an ESR level 28mm/hour at screening and pre-dose
The subject has NOT received any biological therapy in the past, including biologicals for the treatment of rheumatoid arthritis
The subject must have liver function tests including alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (ALP) within 3 times ULN at screening. The patient must also have total bilirubin within the ULN at screening.
The subject must have received at least 3 months of methotrexate and must be on a stable dose of methotrexate (up to 25 mg/week) for at least 8 weeks prior to screening and be willing to remain on this dose throughout the study.
If sulfasalazine is being taken in addition to methotrexate, the subject must be on a stable dose for at least 4 weeks prior to screening and be willing to remain on this dose throughout the study.
If hydroxychloroquine or chloroquine is being taken in addition to methotrexate, the subject must be on a stable dose for at least 3 months prior to screening and be willing to remain on this dose throughout the study.
Those subjects on other oral anti-rheumatic therapies, which may include Non Steroidal Anti Inflammatory Drugs (NSAIDs), COX-2 inhibitors, oral glucocorticoids e.g. prednisolone (£10mg/day) must be on stable dosing regimens for at least 4 weeks prior to screening and be willing to remain on this regime throughout the study. Subjects receiving intramuscular glucocorticoids e.g methylprednisolone (£120 mg/month) must be on a stable dosing regimen for at least 3 months prior to screening and be willing to remain on this regimen throughout the study.
The subject must be on a stable dose of folate supplements (5 mg/week) for at least 4 weeks prior to do

Exclusion Criteria:

Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination (e.g. haematology parameter outside the normal limits), or ECG (12 Lead or Holter).
The subject has a positive Hepatitis B surface antigen or Hepatitis C antibody result at screening.
The subject has a history of elevated liver function tests on more than one occasion (ALT, AST and ALP > 3 x Upper Limit of Normal (ULN); total bilirubin > 1.5 x ULN) in the past 6 months.
Previous exposure or past infection caused by Mycobacterium tuberculosis
The subject has an acute infection.
The subject has a history of repeated, chronic or opportunistic infections that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
The subject has a history of malignancy, except for surgically cured basal cell carcinoma or females with cured cervical carcinoma (> 2 yrs prior).
The subject has a history of human immunodeficiency virus (HIV) or other immunodeficiency disease.
The subject whose calculated creatinine clearance is less than 50ml/min
The subject has significant cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
The subject has taken cyclosporine, leflonomide, cyclophosphamide or azathioprine within 1 month of screening. Subjects that have taken cyclosporine, leflonomide, cyclophosphamide or azathioprine in the past must have recovered from all drug related adverse events.
The subject has taken gold salts or d-penicillamine within 1 month prior to screening. Subjects that have taken gold salts or d-penicillamine in the past must have recovered from all drug related adverse events.
The subject has received intra-articular glucocorticoids within 1 month of screening.
Recent history of bleeding disorders, anaemia, peptic ulcer disease, haematemesis or gastrointestinal bleeding
Subjects with a history of haematological disease or acquired platelet disorders, including drug-induced thrombocytopaenia, acute idiopathic thrombocytopaenia or von Willebrand's disease.
Subjects with a known risk of intra-cranial haemorrhage including Central Nervous System (CNS) surgery within the last 12 months, arterial vascular malformations, aneurysms, significant closed head trauma within 6 months or any other incident the investigator and/or medical monitor considers to be relevant.
The subject has Hb <10 g/deciliter (dL) and platelet count < 150 x 109/Liter (L)
Donation of blood in excess of 500 ml within a 56 day period prior to dosing
An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness of the male subject to use a condom with spermicide in addition to having their female partner use another form of contraception such as an interuterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants of levonorgestrel or a tubal ligation if the woman could become pregnant for at least 12 weeks after dosing
An unwillingness of female subject of child bearing potential to use adequate contraception, as defined in the study restriction section. If necessary, women of non-child bearing potential (i.e. post-menopausal or surgically sterile e.g. tubal ligation or hysterectomy or bilateral oophorectomy) will be confirmed. Postmenopausal status will be confirmed by serum follicle stimulating hormone (FSH) and oestradiol concentrations at screening. Surgical sterility will be defined as females who have had a documented hysterectomy, tubal ligation or bilateral oophorectomy.
The subject has a history of use of drugs of abuse within 12 months prior to screening.
History of regular alcohol consumption exceeding average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). Subjects who regularly consume more than 12 units of alcohol in a 24h period will also be excluded. 1 unit is equivalent to a half-pint (220ml) of beer/lager or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
Positive pregnancy test or lactating at screening.
Participation in a trial with any investigational drug within 3 months or 5 half-lives (whichever is longer) before

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674635

Locations

Layout table for location information

Australia, Queensland
GSK Investigational Site
Woolloongabba, Queensland, Australia, 4102
Australia, Victoria
GSK Investigational Site
Heidelberg, Victoria, Australia, 3084
GSK Investigational Site
Melbourne, Victoria, Australia, VIC 30004
New Zealand
GSK Investigational Site
Christchurch, New Zealand, 8011
GSK Investigational Site
Hamilton, New Zealand, 2001
GSK Investigational Site
Wellington, New Zealand, 6035
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 115522
GSK Investigational Site
Moscow, Russian Federation, 129327
GSK Investigational Site
Novosibirsk, Russian Federation, 630117
GSK Investigational Site
Smolensk, Russian Federation, 214018
GSK Investigational Site
Yaroslavl, Russian Federation, 150062
Serbia
GSK Investigational Site
Belgrade, Serbia, 11000
GSK Investigational Site
Belgrade, Serbia, 11080
GSK Investigational Site
Niska Banja, Serbia, 18205
Ukraine
GSK Investigational Site
Donetsk, Ukraine, 83114
GSK Investigational Site
Kyiv, Ukraine, 03103
GSK Investigational Site
Kyiv, Ukraine, 03680
GSK Investigational Site
Lviv, Ukraine, 79013
GSK Investigational Site
Zaporizhzhya, Ukraine, 69035

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Layout table for investigator information

Study Director:	GSK Clinical Trials	GlaxoSmithKline

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. This link exits the ClinicalTrials.gov site